FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224132676> ?p ?o ?g. }

• W4224132676 endingPage "72" @default.
• W4224132676 startingPage "62" @default.
• W4224132676 abstract "This single-arm, multicentre, phase I study is the first study of zanubrutinib, a potent, specific, irreversible Bruton tyrosine kinase (BTK) inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. The objectives were to evaluate safety and preliminary anti-tumour activity. Forty-four patients received zanubrutinib 320 mg once daily (QD) (n = 10) or 160 mg twice daily (BID) (n = 34) until disease progression or unacceptable toxicity. 29.5% of patients received zanubrutinib for at least two years. The most common adverse event (AE) and the most common grade 3 or higher AE was neutrophil count decreased (54.5% and 25.0% respectively). Two patients (4.5%) discontinued treatment due to AEs and one treatment-emergent AE led to death. All haemorrhagic events were grade 1-2 (except for one non-serious grade 3 purpura). No second primary malignancies, tumour lysis syndrome, or atrial fibrillation/flutter occurred. The overall response rate was 52.3% (complete response rate, 18.2%). Patients with all cancer subtypes benefited from treatment. BTK C481S/R or L528W mutations were found in zanubrutinib-progressive patients. The safety/efficacy profiles of patients treated with 320 mg QD and 160 mg BID were comparable and similar daily area under the curve (AUC) was achieved. Overall, zanubrutinib was well tolerated and either of these two regimens is clinically practical. Registered at ClinicalTrials.gov (NCT03189524, on 16 June 2017, https://clinicaltrials.gov/ct2/show/NCT03189524)." @default.
• W4224132676 created "2022-04-20" @default.
• W4224132676 creator A5001388908 @default.
• W4224132676 creator A5004271284 @default.
• W4224132676 creator A5006292484 @default.
• W4224132676 creator A5017102600 @default.
• W4224132676 creator A5019979393 @default.
• W4224132676 creator A5023412682 @default.
• W4224132676 creator A5025526717 @default.
• W4224132676 creator A5028465455 @default.
• W4224132676 creator A5030040961 @default.
• W4224132676 creator A5037162064 @default.
• W4224132676 creator A5037740266 @default.
• W4224132676 creator A5037965853 @default.
• W4224132676 creator A5040795581 @default.
• W4224132676 creator A5044433615 @default.
• W4224132676 creator A5066795023 @default.
• W4224132676 creator A5080620314 @default.
• W4224132676 date "2022-04-05" @default.
• W4224132676 modified "2023-09-30" @default.
• W4224132676 title "A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective <scp>Bruton tyrosine kinase</scp> inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies" @default.
• W4224132676 cites W1999128869 @default.
• W4224132676 cites W2037983836 @default.
• W4224132676 cites W2067064694 @default.
• W4224132676 cites W2119147717 @default.
• W4224132676 cites W2142099365 @default.
• W4224132676 cites W2298933471 @default.
• W4224132676 cites W2598700764 @default.
• W4224132676 cites W2614443510 @default.
• W4224132676 cites W2765414225 @default.
• W4224132676 cites W2964310707 @default.
• W4224132676 cites W2972482801 @default.
• W4224132676 cites W2985074019 @default.
• W4224132676 cites W2990231836 @default.
• W4224132676 cites W2997469873 @default.
• W4224132676 cites W3046825703 @default.
• W4224132676 cites W3111753230 @default.
• W4224132676 cites W3176115030 @default.
• W4224132676 cites W3196571391 @default.
• W4224132676 cites W3198627485 @default.
• W4224132676 cites W4224132676 @default.
• W4224132676 cites W82942945 @default.
• W4224132676 doi "https://doi.org/10.1111/bjh.18162" @default.
• W4224132676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35383885" @default.
• W4224132676 hasPublicationYear "2022" @default.
• W4224132676 type Work @default.
• W4224132676 citedByCount "8" @default.
• W4224132676 countsByYear W42241326762022 @default.
• W4224132676 countsByYear W42241326762023 @default.
• W4224132676 crossrefType "journal-article" @default.
• W4224132676 hasAuthorship W4224132676A5001388908 @default.
• W4224132676 hasAuthorship W4224132676A5004271284 @default.
• W4224132676 hasAuthorship W4224132676A5006292484 @default.
• W4224132676 hasAuthorship W4224132676A5017102600 @default.
• W4224132676 hasAuthorship W4224132676A5019979393 @default.
• W4224132676 hasAuthorship W4224132676A5023412682 @default.
• W4224132676 hasAuthorship W4224132676A5025526717 @default.
• W4224132676 hasAuthorship W4224132676A5028465455 @default.
• W4224132676 hasAuthorship W4224132676A5030040961 @default.
• W4224132676 hasAuthorship W4224132676A5037162064 @default.
• W4224132676 hasAuthorship W4224132676A5037740266 @default.
• W4224132676 hasAuthorship W4224132676A5037965853 @default.
• W4224132676 hasAuthorship W4224132676A5040795581 @default.
• W4224132676 hasAuthorship W4224132676A5044433615 @default.
• W4224132676 hasAuthorship W4224132676A5066795023 @default.
• W4224132676 hasAuthorship W4224132676A5080620314 @default.
• W4224132676 hasBestOaLocation W42241326762 @default.
• W4224132676 hasConcept C126322002 @default.
• W4224132676 hasConcept C142424586 @default.
• W4224132676 hasConcept C143998085 @default.
• W4224132676 hasConcept C197934379 @default.
• W4224132676 hasConcept C71924100 @default.
• W4224132676 hasConcept C86803240 @default.
• W4224132676 hasConcept C87355193 @default.
• W4224132676 hasConcept C90924648 @default.
• W4224132676 hasConceptScore W4224132676C126322002 @default.
• W4224132676 hasConceptScore W4224132676C142424586 @default.
• W4224132676 hasConceptScore W4224132676C143998085 @default.
• W4224132676 hasConceptScore W4224132676C197934379 @default.
• W4224132676 hasConceptScore W4224132676C71924100 @default.
• W4224132676 hasConceptScore W4224132676C86803240 @default.
• W4224132676 hasConceptScore W4224132676C87355193 @default.
• W4224132676 hasConceptScore W4224132676C90924648 @default.
• W4224132676 hasIssue "1" @default.
• W4224132676 hasLocation W42241326761 @default.
• W4224132676 hasLocation W42241326762 @default.
• W4224132676 hasLocation W42241326763 @default.
• W4224132676 hasOpenAccess W4224132676 @default.
• W4224132676 hasPrimaryLocation W42241326761 @default.
• W4224132676 hasRelatedWork W2110818089 @default.
• W4224132676 hasRelatedWork W2351796763 @default.
• W4224132676 hasRelatedWork W2351985199 @default.
• W4224132676 hasRelatedWork W2403502999 @default.
• W4224132676 hasRelatedWork W2567738959 @default.
• W4224132676 hasRelatedWork W2699314556 @default.
• W4224132676 hasRelatedWork W2923882796 @default.
• W4224132676 hasRelatedWork W2954318774 @default.
• W4224132676 hasRelatedWork W4297834875 @default.

• next